Exclusive interview with the imminent Professor Rustum Roy prior to his departure from this reality. Prof. Roy held 5 professorships and wrote more than 1,000 papers, articles and books. In this interview he discusses whole person healing, Qigong, Bigu, spiritual healing, John of God (João Teixeira de Faria – João de Deus), quantum physics, materials science, alternative medicine, medical fraud and malpractice and other fascinating topics. This video is a rare interview with a most brilliant and important person.
Sometimes Tumors get so big, it might be beneficial to debunk them. Here is a procedure and a doctor who does it with great success. I saw this in my Gerston Group and it caught my interest.
Dr. A’s Message
A Personal Note
As a surgeon specializing and developing the use of the CO
2 laser for breast cancer removal for over 25 years, and having observed and researched other methods of surgical treatment being utilized, the CO
2 laser is superior to other methods available today. This option of treatment is not under trials and all patients struggling with breast cancer are candidates, providing them the opportunity to have any procedure from microscopic activity to mastectomy and axillary node dissections all performed by the CO
2 laser. This natural approach hastens the recovery process. It not only supports the breast cancer patient physically during surgery and post-operatively, but their emotional well being. When a patient is not traumatized physically, they are able to face the next step of treatment with empowerment. Read More
In the first of these studies it is described for the first time in history the eradication of a major oncogene (HER-2) in a breast cancer patient whose breast cancer was eradicated following The Swiss Protocol.
In the second study, the successful approach to metastatic pancreatic cancer is described along with the molecular interaction between oleic acid-GcMAF (OA-GcAMF or Goleic) and a major tumor suppressor gene (p53).
In the third study, the successful approach to incurable brain cancer is described along with the the molecular interaction between Goleic and a major oncogene involved in brain cancer (BCl-6). In this study, The Swiss Protocol for brain cancer by Marco Ruggiero, a protocol that involves the use of transcranial ultrasonography, is revealed for the first time. It is worth noticing that this study was performed in collaboration with a major oncology hospital in central London, UK.
In all three studies, Prof. Ruggiero and colleagues demonstrate for the first time that the plethora of biological activities observed when treating patients with Goleic has to be ascribed to the presence of intrinsically disordered domains (IDD) in the molecular structure of GcMAF. An IDD is a domain that lacks a fixed or ordered three-dimensional structure. read more
For over 10 years this doctor in Texas has healed terminally sick people. Countless trials from the FDA, he won them all, but they keep coming.
Here is a collection of cancer patients who used an alternative route to heal their cancers.
A replacement therapy called GcMAF, which is undergoing pre-clinical trials worldwide, has been proven to eradicate stage-4 cancer. Symptoms have either improved or been completely eradicated in around 85% of the 700 people who had cancers ranging from breast, liver and prostate to bladder and ovarian cancer.
Results have been most successful in patients who have followed a strict no-sugar diet along with a high intake of vitamin D3, largely derived from the sun.
GcMAF, which stands for Gc-protein-derived Macrophage Activating Factor, was discovered in 1990 by Japanese scientist Dr Yamamoto who found that all healthy humans have natural GcMAF and it kickstarts the immune system to fight disease.
20 years later, biomedical company Immuno Biotech has made GcMAF available as a replacement therapy. Its scientists initially produced First Immune GcMAF and have since developed a more potent protein, GOleic, which takes the GcMAF molecule and combines it with Oleic acid and Vitamin D.
GcMAF has been the subject of intense scientific research in recent years. More than 60 peer-reviewed research papers have been produced by 154 scientists who have trialled it on a range of viral and neurological conditions, such as advanced cancer, autism, chronic fatigue syndrome and the rare disorder LMBBS.
Scientists at Immuno Biotech published 16 peer-reviewed papers in 2013. These have appeared in OncoImmunology, Frontiers in Neuroscience and Nutrients, where a paper about GcMAF and cancer cell apoptosis reached the top 5% most-read scientific papers of all time.
Scientific director of Immuno Biotech, Marco Ruggiero, has worked with cancer for 30 years and is now having success with an advanced ultrasonography technique to target tumours directly with GcMAF. Ruggiero, also a medical doctor, says: “GcMAF is not a drug but an essential component of our body, just like insulin. When we are unable to produce these essential components, a number of diseases arise. All these diseases can be reverted by administration of the missing component. In my opinion, the importance of GcMAF derives from this consideration. It is a physiologic protein that is essential for a very large number of functions in our body.”
Video of GcMAF at work